Current recommendations and recent progress in endometrial cancer

CA Cancer J Clin. 2019 Jul;69(4):258-279. doi: 10.3322/caac.21561. Epub 2019 May 10.


Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite-instable, metastatic disease, anti- programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.

Keywords: endometrial cancer; health disparities; microsatellite instability; uterine cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Chemotherapy, Adjuvant
  • Cytoreduction Surgical Procedures
  • Endometrial Neoplasms / genetics
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / therapy*
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Hysterectomy
  • Lymph Node Excision
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local / therapy
  • Prognosis
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Sentinel Lymph Node / pathology
  • Sentinel Lymph Node / surgery


  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • pembrolizumab